Chemed Corp — Hospice Scale, Plumbing Cash Flow, and a Demographic Tailwind

Chemed Corp is a Delaware-incorporated holding company that operates two wholly owned subsidiaries, each a leader in its respective field.

VITAS Healthcare is the largest provider of hospice services in the United States, delivering palliative and end-of-life care to terminally ill patients, predominantly in their own homes and in assisted-living and skilled-nursing settings, with a smaller inpatient footprint. Revenue is billed primarily to Medicare under the hospice per-diem benefit, with smaller contributions from Medicaid, commercial insurers, and the Department of Veterans Affairs. VITAS operates across a broad multi-state footprint and derives revenue from four levels of care — routine home care, continuous care, general inpatient, and respite — with routine home care the volume anchor and continuous care the margin and acuity differentiator.

Roto-Rooter is North America's largest provider of plumbing, drain cleaning, and water restoration services, operating a hybrid model of company-owned branches and franchised locations. Revenue comes from residential and commercial service calls, with additional streams from franchise royalties, national account contracts, and the sale of related products. The brand's national advertising presence and dispatch infrastructure give it a customer-acquisition advantage that local competitors cannot match.

Customers and scale. The customer base is structurally distinct across segments: VITAS serves patients and families referred by physicians, hospitals, and discharge planners, with Medicare as the payer of record for the majority of revenue; Roto-Rooter serves homeowners, property managers, and commercial facilities. Consolidated scale is in the mid-single-digit billions of revenue with a market capitalization of $7.2B, 13.07M shares outstanding, and a workforce dominated by clinicians and field technicians. The dual-segment structure is deliberate: it diversifies reimbursement risk, blends a regulated healthcare cash flow with a consumer-services cash flow, and produces the low-beta profile (0.51) that income and defensive-growth mandates find attractive.

Near term (next 12–24 months). The most visible drivers are Medicare hospice rate updates, VITAS average daily census growth, and Roto-Rooter same-branch revenue. Hospice admissions should continue to grow as referral relationships with hospital systems and accountable care organizations deepen, and as VITAS fills capacity in existing service areas rather than adding new ones — a lower-cost growth mode. Roto-Rooter should benefit from continued pricing realization and branch densification. Margin recovery from labor normalization is the largest near-term earnings lever, with each 100bp of consolidated margin worth roughly $2–3 of EPS.

Medium term (3–5 years). Three structural drivers dominate. First, demographic volume: the 85+ population grows faster than the overall population through the next decade, and hospice penetration among eligible decedents still has room to rise toward mature-market levels. Second, acuity and payer mix: growth in continuous care and inpatient levels, plus incremental VA and managed-care contracts, lifts revenue per patient day. Third, capital deployment: free cash flow funds both buybacks against a small 13.07M share count and tuck-in hospice acquisitions that add census in adjacent geographies. Offsetting these, the CMS payment model continues to migrate toward carve-outs and value-based arrangements, and Roto-Rooter's growth is tethered to housing turnover and remodeling activity, which are rate-sensitive.

Historical figures are indicative of reported trajectory; projections are analyst estimates derived from segment-level assumptions described below.

The model is driven by segment-level arithmetic. VITAS revenue grows with average daily census (low-to-mid single digits) plus revenue per patient day (low single digits from rate updates and acuity mix), producing high-single-digit segment growth with operating margin expanding modestly as labor productivity improves. Roto-Rooter grows mid-single digits on same-branch revenue plus branch additions, with stable-to-slightly-rising margins as pricing outpaces technician wage inflation. Consolidated operating margin expands roughly 40–50bp per year, and the share count declines 2–3% annually from buybacks, so EPS growth of ~10% exceeds operating income growth of ~8%. Note that trailing reported EPS of $19.88 on the current $552.00 price implies a ~27.8x P/E, consistent with a premium defensive compounder trading near the top of its 52-week range of $365.21–$559.72.

Market size. US hospice spending is estimated in the low-to-mid $20 billions annually and grows with the 65+ population and penetration. US plumbing, drain, and restoration services represent a fragmented market of well over $100B in aggregate spend, of which branded national players hold a small single-digit share — the structural opportunity for Roto-Rooter is consolidation of a highly fragmented local trade.

Competitive positioning. In hospice, VITAS competes on scale, clinical quality scores, referral relationships, and the ability to serve high-acuity patients — continuous care capability is a genuine moat because it requires 24/7 staffing depth that smaller providers cannot economically maintain. In plumbing, Roto-Rooter's moat is brand recall, national dispatch infrastructure, and franchise density, which drive lower customer-acquisition cost per job than independents.

Chemed's distinguishing feature versus these peers is the Roto-Rooter hedge: no pure-play hospice or home-health competitor has a non-healthcare, non-discretionary service business attached, which is why CHE's beta of 0.51 sits well below the healthcare-services group average and why its earnings have historically been less sensitive to reimbursement headline risk.

DCF framework. A ten-year discounted cash flow with a 7.5–8.5% weighted average cost of capital (appropriate given the 0.51 beta, minimal leverage, and regulated cash flows), terminal growth of 2.5–3.0%, and free cash flow growing from roughly $405M in 2025E at a high-single-digit rate implies an intrinsic value range of approximately $520–$620 per share. The midpoint near $570 rests on two assumptions that matter most: sustained ~6% revenue growth and continued 40–50bp annual margin expansion. A 100bp shortfall in terminal margin would reduce the DCF value by roughly $45–55 per share, which frames the downside case.

Comparable multiples. At $552.00 and $7.2B market cap, CHE trades at ~27.8x trailing EPS of $19.88 and roughly 17.8x 2025E free cash flow — a premium to healthcare-services peers that is justified by the low beta, the buyback-driven EPS compounding, and the non-healthcare revenue hedge.

CHE's premium multiple is defensible only if margin expansion continues; the stock's position at the top of its 52-week range ($365.21–$559.72) and today's +8.43% move suggest the market has already begun to price in that improvement, leaving limited room for multiple expansion and making earnings delivery the sole return driver from here.

• Medicare reimbursement risk: VITAS derives the majority of revenue from Medicare hospice per-diem rates. A lower-than-expected annual update, a change to the wage index, or expansion of value-based carve-outs could compress segment margins faster than cost actions can offset.
• Labor cost and staffing availability: Nurse and technician shortages drive wage inflation and contract-labor usage. A reacceleration of turnover or a step-up in clinical compensation would directly erode the 40–50bp annual margin expansion central to the earnings model.
• Regulatory and audit exposure: Hospice is subject to intensive CMS scrutiny on eligibility, length of stay, and live-discharge patterns. Targeted audits or payment suspensions in key service areas could disrupt census and add compliance costs.
• Roto-Rooter cyclicality and housing sensitivity: While non-discretionary, plumbing and restoration demand correlates with housing turnover, remodeling spend, and interest rates. A prolonged housing slowdown would pressure same-branch revenue growth and franchise royalties.
• Valuation and liquidity risk: At ~27.8x trailing earnings and near the 52-week high, the stock has little cushion for execution misses. Average volume of 0.15M shares against an 11.85M float means institutional exits are slow, and 5.38% short interest can amplify volatility in either direction.